ABSTRACT. This study aimed to investigate the properties of mutations of the active efflux pump genes acrA/B and tolC in Escherichia coli CVCC 1547 when induced by different drugs. The mutations were isolated in vitro by exposing E. coli CVCC 1547 to stepwise increases in the concentration of ceftriaxone (CRO), amikacin (AMK), or ciprofloxacin. The results showed that the minimum inhibitory concentrations for the corresponding drugs increased, as did the minimum inhibitory concentrations for other fluoroquinolones and β-lactam drugs that were not inducers. DNA sequence analyses of the acrA/B and tolC genes of the mutants and comparison with the parent strain revealed that genetic variations had occurred. Three point mutations resulted in amino acid changes in the proteins expressed. Specifically, strain CRO 10 had a mutation in acrA, A309G, that resulted in a Thr-103 to Ala substitution, and a mutation in tolC, G735A, that changed Ala-245 to Thr; strain AMK 20 (and AMK 30 ) had a Val-447 to Ile amino acid change in acrB. In addition to the missense mutations in these strains, we detected 7, 20, and 15 nonsense mutations in acrA, acrB, and tolC, respectively. To sum up, multiple genetic sequence variations and some changes in amino acid sequences were detected when E. coli CVCC 1547 was challenged in vitro with CRO, AMK, or ciprofloxacin. These changes may have given rise to multidrug-resistant strains.
INTRODUCTION
Escherichia coli is a well-studied bacterium, often used in research at the forefront of advancing technology. Currently, all sequenced pathogenic E. coli strains have come from human hosts (Perna et al., 2001; Welch et al., 2002; Brzuszkiewicz et al., 2006; Chen et al., 2006) . This bias has left a gap in our knowledge as many E. coli strains cause important and widespread diseases in animals, including those consumed by humans. We, therefore, wanted to investigate gene mutations in an E. coli strain representative of those from animal sources and chose the standard E. coli O 73 CVCC 1547 strain (duck origin) as the object of study. Avian pathogenic E. coli strains cause respiratory disease and septicemia in poultry and are economically important worldwide, causing significant mortality. This is an increasing threat to public health owing to the emergence of multidrug-resistant (MDR) E. coli strains.
Efflux pump genes exist both in sensitive and drug-resistant bacteria. Some are induced by their substrates so that a sensitive strain could overexpress a pump and become resistant (Piddock, 2006) . E. coli has been found to possess a variety of active efflux systems such as AcrABTolC, AcrEF-TolC (Jellen-Ritter and Kern, 2001), AcrAD-TolC (Rosenberg et al., 2000; Poole, 2004) , OqxAB (Hansen et al., 2004) , MdfA (Poole, 2004) , FloR (Schwarz et al., 2004) , and MacAB-TolC (Kobayashi et al., 2001 ). The first 4 belong to the RND pump family, and the last 3 to the MF, MF, and ABC pump families, respectively. In all of the above pumps, AcrAB-TolC provides the "overriding" phenotype of intrinsic drug resistance to compounds unrelated in structure. Other pumps may have overlapping substrate repertoires but are generally silent and under tight control by regulatory genes. The substrate range for AcrAB-TolC is the most extensive, including drugs such as β-lactams, fluoroquinolones, glycylcyclines, macrolides, and oxazolidinones.
In recent years, many studies have been performed to elucidate the structure and function of AcrAB-TolC, mainly in E. coli, but mutations and amino acid changes have not been reported in the active efflux genes acrA/B or tolC in drug-induced strains. It has already been demonstrated that knockout of acrA/B or the tolC gene of E. coli increases the sensitivity to drugs (Jellen-Ritter and Kern, 2001) and that increased expression of acrA/B or tolC can greatly increase the drug resistance level (Bailey et al., 2006) . However, no report has investigated the association between point mutations in the above genes induced by sub-MIC drug concentration and MDR.
To better understand the mechanisms of MDR induced by sub-minimum inhibitory concentrations (MIC) in E. coli of animal origin, data need to be collected from sub-MICinduced strains to assess the risks of increasing fluoroquinolone and β-lactam resistance. In this study, the standard strain, E. coli O 73 CVCC 1547 (duck origin), was induced in vitro with ceftriaxone (CRO), a third-generation cephalosporin, amikacin (AMK), an aminoglycoside antibiotic, and ciprofloxacin (CIP), a synthetic fluoroquinolone drug. We compared the MIC values for the parent strain with those of strains having point mutations in acrA/B or tolC. Thus, we investigated the roles played by amino acid mutations in these E. coli genes in MDR to clarify the potential dangers of the misuse of low antibiotic doses in the clinic.
MATERIAL AND METHODS

Bacterial strain
E. coli CVCC 1547 and ATCC 25922 were purchased from the China Institute for Veterinary Drug Control and the Beijing Standard Microbiology Strain Store Center, respectively.
Chemicals and antibacterial agents
CRO, CIP, and AMK were purchased from the National Institute for the Control of Pharmaceutical and Biological Products; all were dissolved in accordance with manufacturer recommendations.
Multicycle induction in vitro and antimicrobial susceptibility tests
The E. coli CVCC 1547 parent strain is susceptible to CRO, CIP, and AMK, according to the Clinical and Laboratory Standards Institute broth micro-diffusion test method (CLSI, 2009), with MICs of 0.5, 2, and 1 μg/mL, respectively. It was used for in vitro induction for up to 30 generations. Drug-induced strains were sampled after 10, 20, and 30 generations for testing. These were identified as CRO 10 , CRO 20 , and CRO 30 ; AMK 10 , AMK 20 , and AMK 30 ; and CIP 10 , CIP 20 , and CIP 30 for CRO, AMK, and CIP, respectively. The MIC for each agent was determined for all samples. E. coli ATCC 25922 was used as a quality control strain. All MICs were determined on at least three independent occasions.
Cross-resistance test
MIC values were determined for agents that were not used in the inductions. We compared the MICs of two other fluoroquinolone agents with CIP and of three other β-lactam agents with CRO.
PCR amplification and DNA sequence analysis of the acrA/B and tolC genes E. coli genomic DNA was prepared using a TIANamp Micro DNA Purification Kit (Tiangen), according to the manufacturer protocol. DNA fragments containing the acrA/B and tolC genes were amplified by PCR using the primers shown in Table 1 . All PCR amplicons were verified by gel electrophoresis on a 1.0% agarose gel (w/v) stained with ethidium bromide. The above amplicons were purified, ligated into the pMD-18T vector (TaKaRa) and sequenced. Sequence analyses were performed online using BLAST (www.ncbi.nlm.nih.gov/blast/). 
RESULTS
Induction of resistant mutants of E. coli
Under drug-selective laboratory conditions, point mutations of an active efflux pump can broaden its drug substrate range (Mao et al., 2002) . Moreover, the "natural pools" of isolates studied thus far generally have undefined regulation-based adaptations that alter the expression levels of homologous pump systems (Wang et al., 2001; Chen et al., 2007; Poole, 2007) .
In order to examine the mechanisms of fluoroquinolone and β-lactam resistance in E. coli, a series of mutants originating from E. coli CVCC 1547 were isolated. MICs were measured for mutants isolated after antibiotic induction for different times. After 10 generations of growth with induction, the results showed that sensitivity to the inducing drug dropped remarkably, with MIC values increasing to 1024 (CRO), 64 (AMK), and 16 (CIP) times that of the parent strain, CVCC 1547. After 20 generations, the MICs increased to >1024, 256, and 64 times the MIC of the parent strain. From the 21st to the 30th generation, MICs did not further increase except for the CIP 30 mutants, where the MIC was twice that of the CIP 20 isolates. The results are presented in Table 2 . CRO = ceftriaxone; AMK = amikacin; CIP = ciprofloxacin; FEP = sodium cefepime; CEF = ceftiofur; CTX = cefotaxime; GAT = gatifloxacin; LVX = levofloxacin. The parent strain was sensitive to CRO, CIP, and AMK. For the first 10 generations of induction, the resistance level increased rapidly. In contrast, the resistance increased slowly from the 10th generation onwards, and, by the 30th generation, all strains had high resistance to the inducing drug. Clearly, the sensitive parent strain had become highly resistant under the pressure of antibiotic selection.
Cross-resistance results
The induced strains resistant to CRO were also completely resistant to the other β-lactam agents, ceftiofur and cefotaxime, and 57% (4/7) were resistant to another β-lactam, sodium cefepime. There was 100% cross-resistance to the three fluoroquinolones CIP, gatifloxacin, and levofloxacin (Table 2) . A previous report had suggested that even silent muta-tions could alter the structure and hence change the substrate specificity of the multidrug efflux pump, AcrAB-TolC (Kimchi-Sarfaty et al., 2007) . We speculated that mutations in the acrA/B and tolC genes contributed to the MDR of the strains induced. In the following study, we sequenced these genes and analyzed the relationship between them.
DNA sequence analysis of the acrA/B and tolC genes from resistant mutants
After amplification, purification, and ligation of the acrA/B and tolC genes from the above induced and parental strains, sequence analysis was conducted. No deletions were found of the active efflux genes acrA/B and tolC.
CIP 10 had the same mutations as strains CIP 20 , CIP 30 , CRO 20 , and CRO 30 . Similarly, AMK 20 had the same mutations as AMK 30 (Table 3 ). The acrA/B and tolC gene sequences of the drug-induced strains in this study were compared with the GenBank sequences (accession No. CP001846). We identified base changes that, in some of the strains, would give rise to amino acid changes in the encoded proteins. /CRO 30 )  G977A, T1226C, G1256T,  G581A, G686T  C1289T, G1391T, A1394T,  T1397C  CRO 10  A309G*, C356A, G419A, T103A  A779G, G800A, A890G,  None  A377T, G410A, A245T  G503A, C527T, G569A,  C980T, G989A, C1130G,  C560T, G581A,  G692A G1211A, T1226C, G1256T, G677A, G735A*, C1289T A782G *Amino acid changes resulted from changes of the base. Table 3 . Gene and amino acid mutations of the acrA/B and tolC genes.
Specifically, for acrA, none of the AMK-induced strains changed compared with the parent strain, CVCC 1547. CIP 10 , CIP 20 , CIP 30 , CRO 20 , and CRO 30 had a single, silent, point mutation, that is, G734A. Interestingly, CRO 10 had 7 point mutations, one of which, A309G, was a missense mutation, resulting in a Thr-103 to Ala change. For acrB, AMK 20 and AMK 30 had 10 point mutations, with one, G1341A, being a missense mutation changing Val-447 to Ile. CIP 10 , CIP 20 , CIP 30 , CRO 20 , and CRO 30 also had 10 point mutations, all of which were silent and 50% (5/10) of which were the same as those of AMK 20 . CRO 10 had 10 point mutations, 20% (2/10) of which were the same as those of AMK 20 , 40% (4/10) were the same as CIP 10 , and all of which were also silent mutations. For tolC, AMK 20 and AMK 30 had 9 point mutations; CIP 10 , CIP 20 , CIP 30 , CRO 20 , and CRO 30 had 4 point mutations, all of which were silent; and 50% (2/4) were the same as those of AMK 20 . CRO 10 had 7 point mutations, with one the same as that of AMK 20 , one the same as CIP 10 , and with a missense mutation, G735A, changing Ala-245 to Thr.
DISCUSSION
Relationship of drug-induced fluoroquinolone resistance with mutations in acrA and acrB in E. coli
Mechanisms of fluoroquinolone resistance fall into two principle categories: alterations in drug targets (such as DNA gyrase or topoisomerase IV) or decreased cellular accumulation of quinolones, involving the major multidrug efflux pump. The latter generally exhibit decreased expression of the OmpF porin and overexpression of the AcrAB efflux pump (Hooper, 2001) . The expression of acrA/B was affected by the regulatory genes marA or soxS (Bratu et al., 2009) . In previous studies, increased expression of marA was observed in CRO 30 , CIP 10 , CIP 20 , CIP 30 , and AMK 20 strains. soxS was overexpressed in CRO 20 , CRO 30 , CIP 20 , CIP 30 , and AMK 20 strains (data not shown). On the other hand, acrB was identified as a mutation of gyrB, a double-point mutation altering two consecutive amino acids (S759R/ R760C) in the COOH-terminal region of the gyrase B subunit. The acrB mutation also significantly reduced the DNA binding of gyrase (Funatsuki et al., 1997) . Mutations at the acrA locus also occurred in response to the deletion of topA encoding topoisomerase I. These mutations help the survival of ΔtopA strains under specific growth conditions. It has been shown that the acrB gene is in the same cistron as gyrB on the genetic map of the E. coli chromosome. Asp-426 and Lys-447 were considered as sites for mutation to quinolone resistance (Funatsuki et al., 1997) . Our experiments show that a Thr-103 to Ala change in acrA and a Val-447 to Ile change in acrB could be evidence of the relationship between fluoroquinolone resistance and active efflux pump mutations.
Alterations in acrA/B and tolC and β-lactam resistance in E. coli
The acrA/B and tolC genes of the CRO 10 -induced strains had the most base sequence changes compared with the parent strain. The number of point mutations was 7, 10, and 7, whereas the numbers for CRO 20 and CRO 30 were reduced to 1, 10, and 4. Moreover, in the CRO 10 strains, there was a single amino acid mutation in each of the acrA and tolC genes. Back mutations occurred in the progression to CRO 20 /CRO 30 . A possible reason is that nonspecific mechanisms play a major role in resistance at the beginning, but with the increased induction times, a number of specific mechanisms (such as production of ESBLs) play a major role; therefore, there is less variation in mutation sites, and no amino acids are changed. In our previous study, we found that, from the 15th generation, strains induced with the above three antimicrobial agents could produce TEM-1 and OXA-1 (data not shown). This may be a possible explanation of the above phenomenon.
Role of aminoglycoside drugs in the induction of acrB
To our knowledge, the AcrAB-TolC transporters have a broad substrate range, including cationic dyes, tetracycline, fluoroquinolone, chloromycetin, erythromycin, β-lactams, and rifampicin, but not hydrophilic aminoglycosides. The substrates of the AcrAD-TolC system are mainly aminoglycosides, bile, and a few amphoteric drugs, but it has no significant affinity for lipophilic drugs or most amphoteric molecules (Rosenberg et al., 2000) . In this study, in order to detect whether aminoglycoside drugs can lead to mutations in acrB, we used an aminoglycoside, AMK, and the results show that AMK induction led to 10 point mutations and one missense mutation in the acrB gene (Table 3) .
In summary, although antibiotics used at concentrations below their MICs cannot kill bacteria, they can modify their physicochemical characteristics and MDR phenotype. In this study, we examined drug-induced E. coli strains, and our results demonstrate that sub-MIC antibiotics can cause alterations in acrA (Thr-103 to Ala), acrB (Val-447 to Ile), and tolC (Ala-245 to Thr) and that the alterations in the acrA and acrB genes may contribute to fluoroquinolone resistance in E. coli.
